Rapid Acquisition of Immunologic Tolerance to Factor VIII and Disappearance of Anti-factor VIII IgG4 after Prophylactic Therapy in a Hemophilia A Patient with High-titer Factor VIII Inhibitor

Journal of Pediatric Hematology/Oncology

Volumn 37, Issue 4, 2015, Pages e220-e222

  Moorehead, Paul C ^a   Thibeault, Lisa ^b   Tuttle, Angie ^c   Grabell, Julie ^c   Dwyre, Louise ^b   Silva, Mariana ^c   James, Paula ^c   Lillicrap, David ^c  

^a New Janeway Childrens Health and Rehabilitation Centre   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

case report; hemophilia A; immune tolerance induction; immunoglobulins; inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN G4; RECOMBINANT BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN G;

ANTIBODY TITER; ARTICLE; CASE REPORT; DISEASE SEVERITY; EXON; FAMILY HISTORY; GENE INSERTION; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFANT; MALE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY;

FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G;

EID: 84937965475     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000287     Document Type: Article

References (8)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9: 418-435.
2. Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16: 256-262.
3. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients: long-term follow-up and continuing experience. Haemophilia. 2012;18:e18-e20.
4. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335-1344.
5. Caram C, de Souza RG, de Sousa JC, et al. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. Thromb Haemost. 2011;105:59-65.
6. Reding MT, Lei S, Lei H, et al. Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost. 2002;88:568-575.
7. Van Helden PMW, van den Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 2008;142:644-652.
8. Whelan SFJ, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013;121:1039-1048.